Albert D Mason Inc. Invests $737,000 in Iradimed Corporation (NASDAQ:IRMD)

Albert D Mason Inc. purchased a new position in shares of Iradimed Corporation (NASDAQ:IRMD) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,659 shares of the medical equipment provider’s stock, valued at approximately $737,000. Albert D Mason Inc. owned about 0.12% of Iradimed as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Copeland Capital Management LLC lifted its holdings in Iradimed by 0.3% in the 3rd quarter. Copeland Capital Management LLC now owns 422,425 shares of the medical equipment provider’s stock valued at $21,244,000 after acquiring an additional 1,433 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Iradimed by 14.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 20,122 shares of the medical equipment provider’s stock worth $1,012,000 after purchasing an additional 2,538 shares in the last quarter. Shaker Investments LLC OH lifted its position in shares of Iradimed by 44.0% in the third quarter. Shaker Investments LLC OH now owns 29,661 shares of the medical equipment provider’s stock worth $1,492,000 after purchasing an additional 9,056 shares in the last quarter. Kings Path Partners LLC lifted its position in shares of Iradimed by 2.3% in the third quarter. Kings Path Partners LLC now owns 24,570 shares of the medical equipment provider’s stock worth $1,236,000 after purchasing an additional 562 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Iradimed in the third quarter worth approximately $147,000. Institutional investors own 92.34% of the company’s stock.

Analyst Ratings Changes

Separately, Roth Mkm reduced their price target on shares of Iradimed from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, August 2nd.

Iradimed Price Performance

NASDAQ IRMD opened at $50.95 on Wednesday. The company has a 50 day simple moving average of $48.00 and a 200-day simple moving average of $45.06. The firm has a market capitalization of $645.23 million, a price-to-earnings ratio of 36.13 and a beta of 0.79. Iradimed Corporation has a 52-week low of $37.51 and a 52-week high of $52.45.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.05. Iradimed had a return on equity of 24.71% and a net margin of 26.83%. The firm had revenue of $17.93 million for the quarter, compared to the consensus estimate of $17.70 million. During the same quarter in the prior year, the company posted $0.33 earnings per share. On average, analysts predict that Iradimed Corporation will post 1.41 EPS for the current year.

Iradimed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Tuesday, August 20th were issued a dividend of $0.15 per share. The ex-dividend date of this dividend was Tuesday, August 20th. This represents a $0.60 annualized dividend and a yield of 1.18%. Iradimed’s dividend payout ratio (DPR) is presently 42.55%.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.